• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Psychosine receptor (GPR65), Truncated

ACP08087

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP08087 Target NameGPR65
Target SynonymsGPR65; TDAG8; Psychosine receptor; G-protein coupled receptor 65; T-cell death-associated gene 8 proteinFormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Protein LengthPartial
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ8IYL9
Background Information
  • Uniprot Id

    Q8IYL9

  • Target Species

    Human

  • Target Name

    GPR65

  • Target Full Name

    Psychosine receptor

  • Target Function

    Receptor for the glycosphingolipid psychosine (PSY) and several related glycosphingolipids. Plays a role in immune response by maintaining lysosome function and supporting phagocytosis-mediated intracellular bacteria clearance. May have a role in activation-induced cell death or differentiation of T-cells.

  • Target Subcellular Location

    Cell membrane; Multi-pass membrane protein.

  • Target Protein Families

    G-protein coupled receptor 1 family

  • Target Tissue Specificity

    Predominantly expressed in thymus, spleen, lymph nodes, small intestine, lung, placenta and peripheral blood leukocytes.

  • Target Synonyms

    GPR65; TDAG8; Psychosine receptor; G-protein coupled receptor 65; T-cell death-associated gene 8 protein

Inquire Recombinant Human Psychosine receptor (GPR65), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification